|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
M05BA04
|
|
gptkbp:CASNumber
|
121268-17-5
|
|
gptkbp:chemicalFormula
|
C4H13NO7P2
|
|
gptkbp:contraindication
|
hypocalcemia
esophageal abnormalities
|
|
gptkbp:drugClass
|
bisphosphonate
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:genericName
|
gptkb:alendronate
|
|
gptkbp:halfLife
|
10 years (in bone)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fosamax
|
|
gptkbp:indication
|
glucocorticoid-induced osteoporosis
prevention of fractures in postmenopausal women
treatment of osteoporosis in men
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
|
|
gptkbp:mechanismOfAction
|
bisphosphonate
inhibits osteoclast-mediated bone resorption
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
hypocalcemia
musculoskeletal pain
esophageal irritation
osteonecrosis of the jaw
|
|
gptkbp:usedFor
|
gptkb:bone
gptkb:Paget's_disease_of_bone
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|